Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - film coated tablets - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - trastuzumab deruxtecan - powder for concentrate for solution for infusion - trastuzumab deruxtecan 100 mg - trastuzumab - her2-positive metastatic breast cancerenhertu is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received a prior anti-her2-based regimen either:• in the metastatic setting, or• in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.her2-low metastatic breast cancerenhertu is indicated for the treatment of adult patients with unresectable or metastatic her2-low (ihc 1+ orihc 2+/ish-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed diseaserecurrence during or within 6 months of completing adjuvant chemotherapyunresectable or metastatic her2-mutant non-small cell lung cancerenhertu is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (nsclc) whose tumors have activating her2 (erbb2) mutations, as detected by an approved test, and who have received a prior systemic therapy. locally advanced or metastatic gastric cancerenhertu is indicated for the treatment of adult patients with locally advanced or metastatic her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagi

Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - water for injections -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - water for injections -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - sodium chloride -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - sodium chloride -

Israel - engelsk - Ministry of Health

astra zeneca (israel) ltd - olaparib - hard capsule - olaparib 50 mg - olaparib - lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed brca-mutated (germline and/or somatic) high grade serous epithelial ovarian cancer, (including fallopian tube, or primary peritoneal) cancer who are in response (complete response or partial response) to platinum-based chemotherapy.